## Highlights of This Issue 3297

### HIGHLIGHTS

**Special Report**

- **3299** AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development
  
  Samir N. Khleif, James H. Doroshow, and William N. Hait; for the AACR-FDA-NCI Cancer Biomarkers Collaborative

**CCR Translations**

- **3319** ADAM-17: A Target to Increase Chemotherapeutic Efficacy in Colorectal Cancer?
  
  Adam M. Lee and Robert B. Diasio
  
  *See article p. 3378*

**CCR New Strategies**

- **3322** New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK
  
  Giorgia Zadra, Carmen Priolo, Akash Patnaik, and Massimo Loda

### MOLECULAR PATHWAYS

- **3329** Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
  
  Christine A. Pratilas and David B. Solit

- **3335** The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment
  
  Ivor Caro and Jennifer A. Low

### HUMAN CANCER BIOLOGY

- **3340** **BRCA1** Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood
  
  Natalia Bednarz, Elke Eltze, Axel Semjonow, Michael Rink, Antje Andreas, Lennart Mulder, Juliane Hannemann, Margit Fisch, Klaus Pantel, Heinz-Ulrich C. Weier, Krzysztof P. Bielawska, and Burkhard Brandt

---

**CANCER THERAPY: PRECLINICAL**

- **3378** Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer
  
  Joan N. Kyula, Sandra Van Schaeybroeck, Joanne Doherty, Catherine S. Fenning, Daniel B. Longley, and Patrick G. Johnston
  
  *See commentary p. 3319*

- **3390** The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells *In vitro and In vivo*
  

- **3399** Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy
  
  Darya Alizadeh, Leping Zhang, Christine E. Brown, Omar Farrukh, Michael C. Jensen, and Behnam Badie

---

Immunohistochemical Detection of **EGFR** Mutation Using Mutation-Specific Antibodies in Lung Cancer

Atsuko Kitamura, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, and Yasushi Yatabe

Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome

Göran Jönsson, Christian Busch, Stian Knappskog, Jürgen Geisler, Hrvoje Miletic, Markus Ringnér, Johan R. Lillehaug, Åke Borg, and Per Eystein Lønning

A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas

Dorine A. Bax, Alan Mackay, Suzanne E. Little, Diana Carvalho, Marta Viana-Pereira, Narinder Tamber, Anita E. Grigoridiadis, Alan Ashworth, Rui M. Reis, David W. Ellison, Sefa Al-Sarraj, Darren Hargrave, and Chris Jones
Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR
Kimberly Laskie Ostrow, Mohammad O. Hoque, Myriam Loyo, Marianna Brait, Alissa Greenberg, Jill M. Siegfried, Jennifer R. Grandis, Autumn Gaither Davis, William L. Bigbee, William Rom, and David Sidransky

Diverse Associations between ESRI Polymorphism and Breast Cancer Development and Progression
Shian-ling Ding, Jyh-Cherng Yu, Shou-Tung Chen, Giu-Cheng Hsu, Huan-Ming Hsu, Jar Yi Ho, Yu Hsin Lin, Chien-Ching Chang, Cathy S.J. Fann, Chun-Wen Cheng, Pei-Ei Wu, and Chen-Yang Shen

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaire, Denis Soulieres, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari, and Susan M. Domchek

Results from a Phase I Clinical Study of the Novel II-Key/HER-2/neu (776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
Sonia A. Perez, Nikoletta L. Kallinteris, Stratos Bisias, Panagiotis K. Tzonis, Katerina Georgakopoulou, Marighoula Varla-Leftherioti, Eric von Hofe, and Constantin N. Baxevanis

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
ABOUT THE COVER

High-grade gliomas are among the deadliest of human cancers and appropriate glioma mouse models that are conveniently applicable for therapy-intervention studies can contribute to the finding of more efficacious treatments. Following the intracranial injection of lentiviral Cre-recombinase vectors into $\textit{LoxP}$-conditional $p53$(or $\textit{pten})$; $\textit{Ink4a}/Arf$; $K-Ras^v12$; $\textit{LucR}$ mice, noninvasively visible high-grade gliomas arise with a short tumor latency that show features commonly found in human high-grade glioma, such as a high mitotic index, nuclear atypia, pseudopalisading necrosis, and giant cell formation. For further details, please see the article by de Vries and colleagues on page 3431 of this issue.